Mutations and copy number variations in circadian clock genes, such as ARNTL2 in colorectal cancer and NPAS2, CLOCK, and PER3 in breast cancer, are linked to cancer progression, suggesting their potential as biomarkers for cancer risk and prognosis.101. This evidence concerns the gene CLOCK and colorectal cancer.